Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences, Inc. (VTYX)
:VTYX
VTYX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.34 - $8.48
Previous CloseN/A
Volume4.54M
Average Volume (3M)1.04M
Market Cap
$101.72M
Enterprise Value-$109.73M
Total Cash (Recent Filing)$27.26M
Total Debt (Recent Filing)$10.79M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
May 08, 2025EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding71,130,050
10 Day Avg. Volume765,113
30 Day Avg. Volume1,041,515
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.75
Forecast
1Y Price Target
$15.33Price Target Upside972.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Ventyx Biosciences News
PremiumCompany Announcements
Ventyx Biosciences Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Ventyx Biosciences Unveils 2025 Pipeline and Clinical Updates
PremiumCompany Announcements
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress---
Bulls Say, Bears Say
Bulls Say
Financial ResourcesVentyx Biosciences has sufficient financial resources, with $252.9 million in cash and marketable securities expected to fund operations into at least the second half of 2026.
Partnership PotentialThe company is working to identify a potential partner or source of alternative non-dilutive financing to progress S1P receptor modulator tamuzimod into late-stage development for ulcerative colitis.
Bears Say
Investor SentimentThe short interest in Ventyx Biosciences is 11.2% of the float, which might indicate some investor skepticism or expectation of stock price decline.
---
Ownership Overview
29.71% Insiders
9.28% Mutual Funds
23.63% Other Institutional Investors
28.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VTYX FAQ
What was Ventyx Biosciences, Inc.’s price range in the past 12 months?
Ventyx Biosciences, Inc. lowest stock price was $1.34 and its highest was $8.48 in the past 12 months.
What is Ventyx Biosciences, Inc.’s market cap?
Ventyx Biosciences, Inc.’s market cap is $101.72M.
When is Ventyx Biosciences, Inc.’s upcoming earnings report date?
Ventyx Biosciences, Inc.’s upcoming earnings report date is May 08, 2025 which is in 56 days.
How were Ventyx Biosciences, Inc.’s earnings last quarter?
Ventyx Biosciences, Inc. released its earnings results on Feb 27, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.527 by $0.117.
Is Ventyx Biosciences, Inc. overvalued?
According to Wall Street analysts Ventyx Biosciences, Inc.’s price is currently Undervalued.
Does Ventyx Biosciences, Inc. pay dividends?
Ventyx Biosciences, Inc. does not currently pay dividends.
What is Ventyx Biosciences, Inc.’s EPS estimate?
Ventyx Biosciences, Inc.’s EPS estimate is -0.48.
How many shares outstanding does Ventyx Biosciences, Inc. have?
Ventyx Biosciences, Inc. has 71,130,050 shares outstanding.
What happened to Ventyx Biosciences, Inc.’s price movement after its last earnings report?
Ventyx Biosciences, Inc. reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.527. Following the earnings report the stock price went up 8.966%.
Which hedge fund is a major shareholder of Ventyx Biosciences, Inc.?
Currently, no hedge funds are holding shares in VTYX
---
Ventyx Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.33 (972.03% Upside)
$15.33 (972.03% Upside)
Blogger Sentiment
Bearish
VTYX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 9.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $250.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.66%
12-Months-Change
Fundamentals
Return on Equity
-54.27%
Trailing 12-Months
Asset Growth
-0.54%
Trailing 12-Months
Company Description
Ventyx Biosciences, Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
---
VTYX Stock 12 Month Forecast
Average Price Target
$15.33
▲(972.03% Upside)
Technical Analysis
Best Analysts Covering VTYX
1 Year
1 Year Success Rate
6/23 ratings generated profit
1 Year Average Return
-18.06%
reiterated a buy rating 14 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 26.09% of your transactions generating a profit, with an average return of -18.06% per trade.
---